Mather Richard G, Hopkins Heidi, Parry Christopher M, Dittrich Sabine
Malaria and Fever Program, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland.
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
BMJ Glob Health. 2019 Oct 31;4(5):e001831. doi: 10.1136/bmjgh-2019-001831. eCollection 2019.
Typhoid fever is one of the most common bacterial causes of acute febrile illness in the developing world, with an estimated 10.9 million new cases and 116.8 thousand deaths in 2017. Typhoid point-of-care (POC) diagnostic tests are widely used but have poor sensitivity and specificity, resulting in antibiotic overuse that has led to the emergence and spread of multidrug-resistant strains. With recent advances in typhoid surveillance and detection, this is the ideal time to produce a target product profile (TPP) that guides product development and ensure that a next-generation test meets the needs of users in the resource-limited settings where typhoid is endemic.
A structured literature review was conducted to develop a draft TPP for a next-generation typhoid diagnostic test with minimal and optimal desired characteristics for 36 test parameters. The TPP was refined using feedback collected from a Delphi survey of key stakeholders in clinical medicine, microbiology, diagnostics and public and global health.
A next-generation typhoid diagnostic test should improve patient management through the diagnosis and treatment of infection with acute serovars Typhi or Paratyphi with a sensitivity ≥90% and specificity ≥95%. The test would ideally be used at the lowest level of the healthcare system in settings without a reliable power or water supply and provide results in <15 min at a cost of <US$1.00.
This report outlines the first comprehensive TPP for typhoid fever and is intended to guide the development of a next-generation typhoid diagnostic test. An accurate POC test will reduce the morbidity and mortality of typhoid fever through rapid diagnosis and treatment and will have the greatest impact in reducing antimicrobial resistance if it is combined with diagnostics for other causes of acute febrile illness in a treatment algorithm.
伤寒热是发展中国家急性发热性疾病最常见的细菌病因之一,2017年估计有1090万新发病例和1.168万例死亡。伤寒即时检测(POC)诊断试验被广泛使用,但灵敏度和特异性较差,导致抗生素过度使用,进而导致多重耐药菌株的出现和传播。随着伤寒监测和检测的最新进展,现在是制定目标产品简介(TPP)的理想时机,该简介可指导产品开发,并确保下一代检测能够满足伤寒流行的资源有限环境中用户的需求。
进行了一项结构化文献综述,以制定下一代伤寒诊断试验的TPP草案,其中包含36个试验参数的最小和最佳期望特征。利用从临床医学、微生物学、诊断学以及公共卫生和全球卫生等关键利益相关者的德尔菲调查中收集的反馈意见,对TPP进行了完善。
下一代伤寒诊断试验应通过诊断和治疗急性伤寒杆菌或副伤寒杆菌感染来改善患者管理,灵敏度≥90%,特异性≥95%。理想情况下,该试验应在没有可靠电力或供水的医疗系统最低级别使用,并在<15分钟内得出结果,成本<1.00美元。
本报告概述了首个全面的伤寒热TPP,旨在指导下一代伤寒诊断试验的开发。一种准确的POC检测将通过快速诊断和治疗降低伤寒热的发病率和死亡率,如果在治疗算法中与其他急性发热性疾病病因的诊断相结合,将对减少抗菌药物耐药性产生最大影响。